108 completed, 43 terminated, 25 unknown, 13 recruiting. 106 Phase 2, 48 Phase 1, 28 Not applicable, 26 Phase 3, 3 Early Phase 1.
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation Non-Interventional Study - Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Recruiting | City of Hope Medical Center | 75 | 2026-11-01 | 2026-10-05 | |
| Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate - Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 1 | Not yet recruiting | City of Hope Medical Center | 12 | 2026-09-30 | 2026-05-28 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT Methotrexate, Anti-CD25 Monoclonal Antibody - Graft Versus Host Disease, Hematologic Neoplasms | Phase 3 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-05-01 | 2026-07-08 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant Belumosudil - Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2025-05-21 | 2026-06-29 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation reduced-dose PTCy, Standard dose PTCY - Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 316 | 2025-01-01 | 2026-03-17 |
| Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP) - Graft Versus Host Disease | Phase 2 | Withdrawn | Molly Gallogly | 2024-10-01 | 2025-01-07 | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine - Graft Versus Host Disease, Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 82 | 2024-07-18 | 2026-01-26 |
| Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment Wharton's jelly mesenchymal stem cells (WJ-MSCs) - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 10 | 2024-06-01 | 2024-03-12 |
| Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Ruxolitinib, Abatacept - Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Recruiting | Washington University School of Medicine | 41 | 2024-05-07 | 2026-04-22 |
| Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease Acute Myeloid Leukemia, Adult, Graft Versus Host Disease | Withdrawn | Ugur Arzu Kulu | 2023-11-15 | 2025-01-29 | ||
| Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD Posaconazole tablet - Invasive Fungal Disease, Graft Versus Host Disease | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2023-08-01 | 2024-11-20 | |
| Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients Chronic Lung Disease, Hematopoietic Cell Transplantation | Recruiting | University of Michigan Rogel Cancer Center | 375 | 2023-05-30 | 2025-10-20 | |
| The Skin Microbiome in Graft Versus Host Disease Skin swabs, Skin punch biopsies, additional blood sampling - Skin Microbiome, Graft Versus Host Disease | Active not recruiting | University Hospital, Basel, Switzerland | 74 | 2023-03-01 | 2025-04-03 | |
| Expressive Writing in GVHD Expressive Writing - Graft Versus Host Disease | Early Phase 1 | Terminated | Northwestern University | 3 | 2023-01-21 | 2025-04-30 |
| Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT Cyclophosphamide - Graft Versus Host Disease | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 35 | 2023-01-01 | 2026-01-06 |
| ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 - Immunodeficiency, Immunosuppression | Not applicable | Terminated | Scripps Translational Science Institute | 2117 | 2022-12-22 | 2025-08-08 |
| A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | ViGenCell Inc. | 12 | 2022-11-20 | 2022-03-11 |
Showing 20 of 207. Sign in to see all of them.
Graft vs Host Disease (207) · Leukemia (60) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (56) · Myelodysplastic Syndromes (55) · Leukemia, Myeloid, Acute (49) · Leukemia, Lymphocytic, Chronic, B-Cell (46) · Lymphoma (44) · Leukemia, Myeloid, Accelerated Phase (43) · Lymphoma, Non-Hodgkin (43) · Lymphoma, Follicular (42) · Leukemia, Myeloid, Chronic-Phase (41) · Lymphoma, Mantle-Cell (41) · Lymphoma, Large B-Cell, Diffuse (40) · Hodgkin Disease (38) · Lymphoma, B-Cell, Marginal Zone (38)
Immune System Diseases (203) · Hemic and Lymphatic Diseases (100) · Hematologic Diseases (93) · Neoplasms (92) · Neoplasms by Histologic Type (81) · Lymphatic Diseases (73) · Immunoproliferative Disorders (71) · Lymphoproliferative Disorders (69) · Bone Marrow Diseases (68) · Pathological Conditions, Signs and Symptoms (67) · Pathologic Processes (66) · Disease Attributes (65) · Leukemia, Myeloid (62) · Chronic Disease (61) · Leukemia, Lymphoid (60)
Cyclophosphamide (44) · Tacrolimus (44) · Cyclosporine (37) · Methotrexate (36) · Methylprednisolone (29) · Antilymphocyte Serum (27) · Busulfan (27) · Mycophenolic Acid (25) · Peripheral Blood Stem Cell Transplantation (22) · fludarabine phosphate (21) · Sirolimus (20) · Melphalan (17) · Radiotherapy (17) · Filgrastim (14) · Whole-Body Irradiation (12)
Fred Hutchinson Cancer Center (18) · City of Hope Medical Center (9) · Dana-Farber Cancer Institute (8) · Roswell Park Cancer Institute (7) · H. Lee Moffitt Cancer Center and Research Institute (5) · Masonic Cancer Center, University of Minnesota (4) · Memorial Sloan Kettering Cancer Center (4) · Nantes University Hospital (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Vanderbilt-Ingram Cancer Center (4) · Emory University (3) · Fairview University Medical Center (3) · Hadassah Medical Organization (3) · Jonsson Comprehensive Cancer Center (3) · Mesoblast, Inc. (3)
United States (145) · France (13) · Canada (9) · Israel (9) · Australia (8) · China (8) · Germany (7) · Italy (5) · Spain (5) · United Kingdom (5) · South Korea (4) · Belgium (3) · Japan (3) · New Zealand (3) · Switzerland (3)
Barbara Jean Bambach, MD (4) · Christopher James, PA (3) · Roger Strair (3) · Stephanie Lee (3) · Corey Cutler, MD, MPH (2) · Gary J. Schiller, MD (2) · Gregory Yanik, MD (2) · H. Joachim Deeg, MD (2) · John E. Wagner, MD (2) · K. Scott Baker (2) · Madan Jagasia, MD (2) · Michael Y Shapira, MD (2) · Moshe Yeshurun, MD (2)
PMID 17889355, PMID 17910637, PMID 17925486, PMID 18769450, PMID 19286996, PMID 19539216, PMID 21149333, PMID 21669298, PMID 21689773, PMID 21874061, PMID 22002488, PMID 22129252, PMID 22157574, PMID 24140121, PMID 24497539, PMID 24530972, PMID 25691106, PMID 25862561, PMID 26033282, PMID 26053664, PMID 26189353, PMID 26378033, PMID 27515308, PMID 28864814, PMID 28924018, PMID 28935847, PMID 29296838, PMID 29326124, PMID 31260802, PMID 32690735, PMID 32973350, PMID 34102349, PMID 34156440, PMID 34242388, PMID 35007144, PMID 36189324, PMID 36624161, PMID 37189240, PMID 37301631, PMID 37647633, PMID 37698591, PMID 39908565, PMID 40353516, PMID 40503088, PMID 42322116, PMID 42532067
P30CA015704 (7), P30CA033572 (7), P01CA015396 (4), P30CA006973 (4), P30CA068485 (3), P30CA072720 (3), P01CA018029 (2), P30CA006516 (2), P30CA012197 (2), P30CA016056 (2), P30CA036727 (2), P30CA043703 (2), U10CA031946 (2), 2009 (1), 2014 (1)